Zacks Research Forecasts AbbVie's Q1 Earnings (NYSE:ABBV)

Key Points

• Analysts from Zacks Research have raised AbbVie's Q1 2027 earnings estimate to $3.19 per share, while the current full-year earnings consensus is $12.31 per share.
• BMO Capital Markets has increased its target price for AbbVie from $215.00 to $240.00 and given the company an "outperform" rating, amidst general optimism reflected in analyst ratings.
• AbbVie recently announced a quarterly dividend of $1.64 per share, representing a 3.0% yield, with a payout ratio of 312.38%.

AbbVie Inc. (NYSE:ABBV - Free Report) - Analysts at Zacks Research boosted their Q1 2027 EPS estimates for shares of AbbVie in a research report issued on Thursday, September 18th. Zacks Research analyst Team now forecasts that the company will earn $3.19 per share for the quarter, up from their prior estimate of $3.18. The consensus estimate for AbbVie's current full-year earnings is $12.31 per share.

AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The company reported $2.97 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.24 by ($0.27). AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The firm had revenue of $15.42 billion during the quarter, compared to analysts' expectations of $14.93 billion. During the same quarter in the previous year, the firm posted $2.65 EPS. AbbVie's revenue was up 6.6% compared to the same quarter last year.

Other analysts have also recently issued reports about the company. Bank of America lifted their price objective on AbbVie to $204.00 and gave the company a "hold" rating in a research report on Monday, June 9th. Berenberg Bank upgraded shares of AbbVie from a "hold" rating to a "buy" rating and upped their price objective for the stock from $170.00 to $270.00 in a report on Wednesday, September 17th. Daiwa Capital Markets upgraded shares of AbbVie from a "neutral" rating to an "outperform" rating and set a $214.00 target price for the company in a report on Thursday, August 7th. Guggenheim boosted their price target on AbbVie from $216.00 to $227.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. Finally, BMO Capital Markets raised their price objective on AbbVie from $215.00 to $240.00 and gave the company an "outperform" rating in a research report on Friday, September 12th. Four equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $223.45.

AbbVie Trading Up 0.3%

NYSE ABBV traded up $0.62 during trading on Monday, hitting $223.09. The company had a trading volume of 5,989,926 shares, compared to its average volume of 4,689,837. The company's fifty day moving average is $203.75 and its 200-day moving average is $194.84. AbbVie has a one year low of $163.81 and a one year high of $225.16. The company has a current ratio of 0.74, a quick ratio of 0.61 and a debt-to-equity ratio of 44.14. The company has a market cap of $394.09 billion, a price-to-earnings ratio of 21.01, a price-to-earnings-growth ratio of 1.33 and a beta of 0.53.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, November 14th. Shareholders of record on Wednesday, October 15th will be issued a dividend of $1.64 per share. The ex-dividend date of this dividend is Wednesday, October 15th. This represents a $6.56 dividend on an annualized basis and a yield of 2.9%. AbbVie's dividend payout ratio (DPR) is currently 312.38%.

Insider Buying and Selling

In other news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $198.42, for a total transaction of $8,407,055.40. Following the transaction, the executive vice president owned 177,292 shares of the company's stock, valued at approximately $35,178,278.64. The trade was a 19.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Nicholas Donoghoe sold 13,295 shares of the stock in a transaction on Tuesday, August 5th. The shares were sold at an average price of $198.51, for a total transaction of $2,639,190.45. Following the completion of the sale, the executive vice president directly owned 58,247 shares in the company, valued at approximately $11,562,611.97. This represents a 18.58% decrease in their position. The disclosure for this sale can be found here. 0.08% of the stock is currently owned by insiders.

Hedge Funds Weigh In On AbbVie

Several institutional investors have recently made changes to their positions in ABBV. Marshall & Sullivan Inc. WA acquired a new stake in AbbVie during the 2nd quarter worth about $25,000. Evolution Wealth Management Inc. acquired a new position in shares of AbbVie in the second quarter worth about $26,000. TD Capital Management LLC raised its stake in shares of AbbVie by 82.9% during the 1st quarter. TD Capital Management LLC now owns 128 shares of the company's stock worth $27,000 after buying an additional 58 shares during the period. Spurstone Advisory Services LLC purchased a new position in AbbVie during the second quarter valued at $28,000. Finally, Abound Financial LLC purchased a new stake in AbbVie during the 1st quarter worth approximately $30,000. Hedge funds and other institutional investors own 70.23% of the company's stock.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.